Phenotypes associated with this allele

• Allele Symbol: Gt(ROSA)26Sor^{tm1(sb11)Njen}
• Allele Name: targeted mutation 1, Nancy A Jenkins
• Allele ID: MGI:3608906
• Summary: 6 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm1(sb11)Njen/Gt(ROSA)26Sor^+ Hprt1^tm1(sb-Onco-Array)Peli/Hprt1^+	involves: 129S7/SvEvBrd	MGI:4843329
cn2	Gt(ROSA)26Sor^tm1(sb11)Njen/Gt(ROSA)26Sor^+ Hprt1^tm1(sb-Onco-Array)Peli/Y	involves: 129S7/SvEvBrd	MGI:4843330
cn3	Gt(ROSA)26Sor^tm1(sb11)Njen/Gt(ROSA)26Sor^+ TgTn(sb-T2/Onc2)6057Njen/0	involves: C3H * C57BL/6	MGI:3613059
cn4	Gt(ROSA)26Sor^tm1(sb11)Njen/Gt(ROSA)26Sor^+ TgTn(sb-T2/Onc2)6070Njen/0	involves: C3H * C57BL/6	MGI:3613060
cn5	Gt(ROSA)26Sor^tm1(sb11)Njen/Gt(ROSA)26Sor^+ TgTn(sb-T2/Onc2)6113Njen/0	involves: C3H * C57BL/6	MGI:3613061
cn6	Gt(ROSA)26Sor^tm1(sb11)Njen/Gt(ROSA)26Sor^+ TgTn(sb-T2/Onc3)12740Njen/0	involves: C3H * C57BL/6J	MGI:4367200

Genotype
MGI:4843329

cn1

• Allelic Composition: Gt(ROSA)26Sor^{tm1(sb11)Njen}/Gt(ROSA)26Sor⁺; Hprt1^{tm1(sb-Onco-Array)Peli}/Hprt1⁺
• Genetic Background: involves: 129S7/SvEvBrd

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:166283 )

♀ • all mice that survive past weaning are sick by 42 days of age

perinatal lethality, incomplete penetrance ( J:166283 )

♀ • fewer than expected mice are found at E18.5 and at birth

postnatal lethality, incomplete penetrance ( J:166283 )

♀ • most survivors die before weaning

neoplasm

increased tumor incidence ( J:166283 )

♀ • live born mice develop a variety of benign and malignant tumors

♀ • mice develop tumors in multiple organs

increased skin squamous cell carcinoma incidence ( J:166283 )

♀

increased rhabdomyosarcoma incidence ( J:166283 )

♀

increased lung adenoma incidence ( J:166283 )

♀

increased hemangioma incidence ( J:166283 )

♀

increased lymphoma incidence ( J:166283 )

♀

increased medulloblastoma incidence ( J:166283 )

♀

increased lung adenocarcinoma incidence ( J:166283 )

♀

increased hemangiosarcoma incidence ( J:166283 )

♀

growth/size/body

decreased birth body size ( J:166283 )

♀ • live born mice are smaller than their control littermates

postnatal growth retardation ( J:166283 )

♀

integument

increased skin squamous cell carcinoma incidence ( J:166283 )

♀

respiratory system

increased lung adenoma incidence ( J:166283 )

♀

increased lung adenocarcinoma incidence ( J:166283 )

♀

nervous system

increased medulloblastoma incidence ( J:166283 )

♀

muscle

increased rhabdomyosarcoma incidence ( J:166283 )

♀

Genotype
MGI:4843330

cn2

• Allelic Composition: Gt(ROSA)26Sor^{tm1(sb11)Njen}/Gt(ROSA)26Sor⁺; Hprt1^{tm1(sb-Onco-Array)Peli}/Y
• Genetic Background: involves: 129S7/SvEvBrd

mortality/aging

premature death ( J:166283 )

♂ • all mice that survive past weaning are sick by 42 days of age

perinatal lethality, incomplete penetrance ( J:166283 )

♂ • fewer than expected mice are found at E18.5 and at birth

postnatal lethality, incomplete penetrance ( J:166283 )

♂ • most survivors die before weaning

neoplasm

increased tumor incidence ( J:166283 )

♂ • live born mice develop a variety of benign and malignant tumors

♂ • mice develop tumors in multiple organs

increased skin squamous cell carcinoma incidence ( J:166283 )

♂

increased rhabdomyosarcoma incidence ( J:166283 )

♂

increased lung adenoma incidence ( J:166283 )

♂

increased hemangioma incidence ( J:166283 )

♂

increased lymphoma incidence ( J:166283 )

♂

increased medulloblastoma incidence ( J:166283 )

♂

increased lung adenocarcinoma incidence ( J:166283 )

♂

increased hemangiosarcoma incidence ( J:166283 )

♂

growth/size/body

decreased birth body size ( J:166283 )

♂ • live born mice are smaller than their control littermates

postnatal growth retardation ( J:166283 )

♂

integument

increased skin squamous cell carcinoma incidence ( J:166283 )

♂

muscle

increased rhabdomyosarcoma incidence ( J:166283 )

♂

nervous system

increased medulloblastoma incidence ( J:166283 )

♂

respiratory system

increased lung adenoma incidence ( J:166283 )

♂

increased lung adenocarcinoma incidence ( J:166283 )

♂

Genotype
MGI:3613059

cn3

• Allelic Composition: Gt(ROSA)26Sor^{tm1(sb11)Njen}/Gt(ROSA)26Sor⁺; TgTn(sb-T2/Onc2)6057Njen/0
• Genetic Background: involves: C3H * C57BL/6

mortality/aging

premature death ( J:102234 )

• all mice that survive past weaning die by 17 weeks of age from cancer

lethality throughout fetal growth and development, incomplete penetrance ( J:102234 )

• only 5.6% (5 of 89) of pups at birth are double mutants and significant loss of these mice is seen at E16 but not at E10

neoplasm

increased tumor incidence ( J:102234 )

• all double mutants develop cancer with a variety of tumor types

increased lymphoma incidence ( J:102234 )

• non-T/non-B cell derived lymphoma is also seen

increased T cell derived lymphoma incidence ( J:102234 )

• most common type of tumor

increased B cell derived lymphoma incidence ( J:102234 )

increased medulloblastoma incidence ( J:102234 )

• some mice develop medulloblastomas

embryo

decreased embryo size ( J:102234 )

• at E10 and E16, many embryos appear smaller than control littermates

growth/size/body

decreased embryo size ( J:102234 )

• at E10 and E16, many embryos appear smaller than control littermates

decreased fetal size ( J:102234 )

• at E16

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:102234 )

• most common type of tumor

nervous system

increased medulloblastoma incidence ( J:102234 )

• some mice develop medulloblastomas

immune system

increased T cell derived lymphoma incidence ( J:102234 )

• most common type of tumor

hematopoietic system

increased T cell derived lymphoma incidence ( J:102234 )

• most common type of tumor

Genotype
MGI:3613060

cn4

• Allelic Composition: Gt(ROSA)26Sor^{tm1(sb11)Njen}/Gt(ROSA)26Sor⁺; TgTn(sb-T2/Onc2)6070Njen/0
• Genetic Background: involves: C3H * C57BL/6

mortality/aging

premature death ( J:102234 )

• all mice that survive past weaning die by 17 weeks of age from cancer

lethality throughout fetal growth and development, incomplete penetrance ( J:102234 )

• only 12.5% (17 of 136) of pups at birth are double mutants and significant loss of these mice is seen at E16 but not at E10

neoplasm

increased tumor incidence ( J:102234 )

• all double mutants develop cancer with a variety of tumor types

increased lymphoma incidence ( J:102234 )

• non-T/non-B cell derived lymphoma is also seen

increased T cell derived lymphoma incidence ( J:102234 )

• most common type of tumor

increased B cell derived lymphoma incidence ( J:102234 )

increased medulloblastoma incidence ( J:102234 )

• some mice develop medulloblastomas

embryo

decreased embryo size ( J:102234 )

• at E10 and E16, many embryos appear smaller than control littermates

digestive/alimentary system

abnormal duodenum morphology ( J:102234 )

• hyperplasia of the duodenum was seen in 2 mice

growth/size/body

decreased embryo size ( J:102234 )

• at E10 and E16, many embryos appear smaller than control littermates

decreased fetal size ( J:102234 )

• at E16

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:102234 )

• most common type of tumor

nervous system

increased medulloblastoma incidence ( J:102234 )

• some mice develop medulloblastomas

immune system

increased T cell derived lymphoma incidence ( J:102234 )

• most common type of tumor

hematopoietic system

increased T cell derived lymphoma incidence ( J:102234 )

• most common type of tumor

Genotype
MGI:3613061

cn5

• Allelic Composition: Gt(ROSA)26Sor^{tm1(sb11)Njen}/Gt(ROSA)26Sor⁺; TgTn(sb-T2/Onc2)6113Njen/0
• Genetic Background: involves: C3H * C57BL/6

mortality/aging

premature death ( J:102234 )

• all mice that survive past weaning die by 17 weeks of age from cancer

lethality throughout fetal growth and development, incomplete penetrance ( J:102234 )

• only 8.3% (9 of 109) of pups at birth are double mutants and significant loss of these mice is seen at E16 but not at E10

neoplasm

increased tumor incidence ( J:102234 )

• all double mutants develop cancer with a variety of tumor types

increased lymphoma incidence ( J:102234 )

• non-T/non-B cell derived lymphoma is also seen

increased T cell derived lymphoma incidence ( J:102234 )

• most common type of tumor

increased B cell derived lymphoma incidence ( J:102234 )

embryo

decreased embryo size ( J:102234 )

• at E10 and E16, many embryos appear smaller than control littermates

endocrine/exocrine glands

pituitary gland hyperplasia ( J:102234 )

• pituitary hyperplasia was seen in 1 mouse

increased T cell derived lymphoma incidence ( J:102234 )

• most common type of tumor

growth/size/body

decreased embryo size ( J:102234 )

• at E10 and E16, many embryos appear smaller than control littermates

decreased fetal size ( J:102234 )

• at E16

nervous system

pituitary gland hyperplasia ( J:102234 )

• pituitary hyperplasia was seen in 1 mouse

immune system

increased T cell derived lymphoma incidence ( J:102234 )

• most common type of tumor

hematopoietic system

increased T cell derived lymphoma incidence ( J:102234 )

• most common type of tumor

Genotype
MGI:4367200

cn6

• Allelic Composition: Gt(ROSA)26Sor^{tm1(sb11)Njen}/Gt(ROSA)26Sor⁺; TgTn(sb-T2/Onc3)12740Njen/0
• Genetic Background: involves: C3H * C57BL/6J

mortality/aging

premature death ( J:153656 )

• compared with Gt(ROSA)26Sor^{tm1(sb11)Njen} mice

neoplasm

increased pheochromocytoma incidence ( J:153656 )

• in one mouse

increased liver tumor incidence ( J:153656 )

• liver tumors metastasize to the lungs

increased hepatocellular carcinoma incidence ( J:153656 )

• 23 tumors in 62 with mice greater prevalent in male than female mice

increased liver adenoma incidence ( J:153656 )

• 58 tumors in 62 mice with greater prevalent in male than female mice

increased adenoma incidence ( J:153656 )

• 23 adenomas with multiple locations develop in 62 mice

increased hemangioma incidence ( J:153656 )

• 7 hemangiomas with multiple locations develop in 62 mice

increased lymphoma incidence ( J:153656 )

• in 11% of mice (7 tumors in 62 mice)

increased T cell derived lymphoma incidence ( J:153656 )

• 3 tumors in 62 mice

increased B cell derived lymphoma incidence ( J:153656 )

• 5 tumors in 62 mice

increased blastoma incidence ( J:153656 )

• in one mouse

increased carcinoma incidence ( J:153656 )

• mice develop carcinomas in the colon (1 tumors in 62 mice), lung (3 in 62), mammary gland (5 in 62), salivary gland (1 in 62), preputial gland (12 in 62), parathyroid (1 in 62), and nasal cavity (1 in 62)

increased basal cell carcinoma incidence ( J:153656 )

• in one mouse

increased lung carcinoma incidence ( J:153656 )

• 3 tumors in 62 mice

increased squamous cell carcinoma incidence ( J:153656 )

• one mouse developed a squamous cell carcinoma in the clitoral gland

• one mouse developed a squamous cell carcinoma in the salivary gland

increased skin squamous cell carcinoma incidence ( J:153656 )

• 27 tumors in 62 mice

increased melanoma incidence ( J:153656 )

• one mouse developed a melanoma

increased sarcoma incidence ( J:153656 )

• 2 sarcomas with multiple locations develop in 62 mice

increased hemangiosarcoma incidence ( J:153656 )

• 4 tumors in 62 mice

integument

increased basal cell carcinoma incidence ( J:153656 )

• in one mouse

increased skin squamous cell carcinoma incidence ( J:153656 )

• 27 tumors in 62 mice

endocrine/exocrine glands

increased pheochromocytoma incidence ( J:153656 )

• in one mouse

increased T cell derived lymphoma incidence ( J:153656 )

• 3 tumors in 62 mice

liver/biliary system

increased liver tumor incidence ( J:153656 )

• liver tumors metastasize to the lungs

increased hepatocellular carcinoma incidence ( J:153656 )

• 23 tumors in 62 with mice greater prevalent in male than female mice

increased liver adenoma incidence ( J:153656 )

• 58 tumors in 62 mice with greater prevalent in male than female mice

respiratory system

increased lung carcinoma incidence ( J:153656 )

• 3 tumors in 62 mice

immune system

increased T cell derived lymphoma incidence ( J:153656 )

• 3 tumors in 62 mice

hematopoietic system

increased T cell derived lymphoma incidence ( J:153656 )

• 3 tumors in 62 mice